TNF and histiocytic sarcoma: Notably, TNF-α inhibitors were associated with minimized secretion, diminished inflammation, alleviated pain, and improved disease severity scores in most cases suffering from moderate-to-severe DCS who failed on antibiotics and retinoids as well as the patients who developed concomitant HS [5, 32, 39, 43, 45–49, 52–61].